Emerging AL amyloidosis treatments: immunotherapies & targeting amyloid plaque deposits
Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, provides an overview of strategies being explored for the treatment of light chain (AL) amyloidosis, and shares insights into therapies under investigation to directly tackle amyloid plaque deposits. Dr Dispenzieri discusses the future use of immunotherapy strategies such as bispecific antibodies and CAR-T cell therapy to treat patients with AL amyloidosis, with anticipation of positive outcomes due to the lower tumor burden of this disease relative to multiple myeloma. Dr Dispenzieri then talks on the antibodies NEOD001 and CAEL-101, which aim to increase the reabsorption of amyloid protein at amyloid fibrils, as well as the use of amyloid-binding peptides to visualize amyloid. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found